DRTS News and Press, Alpha Tau Medical Ltd.

2026-02-24 11:03:49 ET Yi Chen from H.C. Wainwright issued a price target of $12.00 for DRTS on 2026-02-24 15:29:33. The adjusted price target was set to $12.00. At the time of the announcement, DRTS was trading at $7.495. The overall price target consensus is at $9.00 w...

- Approval establishes first clinical authorization outside Israel and initiates post-market surveillance program - - First-in-kind technology delivers intra-tumoral alpha-emitting radiotherapeutics, reflects strength of clinical data and strong collaboration with Japanese regulators and clin...

- Expecting very active 2026 from a clinical perspective, including significant patient accrual completions and subsequent data readouts from ReSTART pivotal skin cancer trial as well as trials in cancers of internal organs including the pancreas and brain - - Ramping U.S. manufacturing for c...

2026-01-23 03:34:45 ET Overview It has been an eventful start to the year for Alpha Tau Medical (DRTS), which I first wrote about back in October as a unique technology/mechanism and a story set to inflect over 2026 and beyond. The stock is up ~70% since my initiation and ~35% Y...

- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation not typical of conventional radiation therapy treatments, as well as potential anti-inflammato...

2026-01-05 12:38:00 ET Radiation therapy has been a foundation of cancer care for more than a century. From early X-ray machines to today’s image-guided systems, the goal has remained the same: deliver enough energy to destroy tumors while sparing healthy tissue. What has changed, gr...

- Initial module submission marks an important milestone in the pre-market approval process -  - Flexible modular submission framework granted to Alpha Tau by the FDA allows for streamlined review and feedback from the FDA as each module is submitted - - Module submitted in parallel ...

2026-01-02 15:00:31 ET More on the markets Realistic Expectations For 2026 Market Rotation Alert: Positioning For A Potentially Tumultuous Year S&P 500 And Bitcoin: After 4 Years Of Mediocrity From The Latter, I Own Both, Here's Why Steady start to 2026: ...

JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ® , today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corpo...

- First patient in the world treated with Alpha DaRT ® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months –...